---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-007480"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2024-01-25T23:59:59+00:00"
generated_at: "2026-06-06T18:28:52.239537+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics regains Nasdaq minimum bid price compliance after reverse split

## Summary
- Received Nasdaq notice on Jan 23, 2024 confirming regained compliance with bid price rule.
- Company conducted a 1-for-10 reverse stock split on Jan 5, 2024 to help meet the $1.00 minimum close.
- Common shares met $1.00 closing bid for 10 consecutive trading days, ending the deficiency.
- Prior non-compliance notice was issued Jan 23, 2023; Nasdaq has now closed the matter.

## SEC filing metadata
- accession: 0000950170-24-007480
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2024-01-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017024007480/0000950170-24-007480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024007480/sabs-20240123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-007480
- JSON: https://secwatch.observer/filing/0000950170-24-007480.json
- Plain text: https://secwatch.observer/filing/0000950170-24-007480.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.